Surgical and Animal Core

我们实验室的一个特点是开发新颖和创新的体内肿瘤模型，使我们能够研究治疗药物输送中的障碍。这是唯一可能的，因为卓越的外科专业知识和独特的动物设施，在斯蒂尔实验室自1975年成立以来。该中心将继续发挥两项主要功能：(i)外科支持，包括新型动物模型的开发；（ii）小鼠的繁殖和维护，包括基因工程小鼠（GEM）。两者都是成功完成所有计划项目拨款（PPG）目标的关键。因此，Core C是这个PPG的基石。该中心将继续发展或改进并提供复杂的原位肿瘤模型-同源肿瘤移植物（所有四个项目）-以及颅窗（项目1），肺窗（项目2），肝脏肿瘤准备（项目2,3）和腹窗（项目4）。这将使在脑、结肠、肝脏和胰腺肿瘤及其转移的原位器官环境中进行分子、细胞、解剖和功能参数的体内时间过程监测成为可能。此外，该核心将在修订后的PPG中显著扩大GEM模型的维护和提供，以满足所有4个项目对GEM的激增需求，以研究宿主微环境在自发性肿瘤治疗反应中的作用。通过他对Cox-7生物实验室的领导。黄博士将继续确保所有实验动物质量一致，不含鼠病毒、致病菌和寄生虫。这将使PPG团队能够在不使用抗生素的情况下进行所有实验程序。这些研究在其他地方极其困难，成本也更高。目前在Cox-7设施中有26种确定菌群的基因工程小鼠系。根据所有4个项目的需要，还将在该设施内设计或重新衍生、繁殖和生产其他小鼠品系。经过筛选且不含小鼠病原体的肿瘤将在体内连续传代，并在菌落内植入实验动物体内。体内肿瘤不会传代超过第五代（F5），以避免肿瘤特征的改变。这确保了对动物和肿瘤质量的严格控制。Core C将继续提供标准的动物程序，如控释泵植入、血管线放置、术后护理和组织收集。

A hallmark of our laboratory is the development of novel and innovative in vivo tumor models that allow us to study barriers in the delivery of therapeutic agents. This is only possible because of the outstanding surgical expertise and unique animal facility available in the Steele Laboratory since its inception in 1975. This Core will continue to serve two major functions: (i) the surgical support, including novel animal model development, and (ii) the breeding and maintenance of mice, including genetically engineered mice (GEM). Both are vital for successful completion of all Program Project Grant (PPG) goals. Thus, Core C is a cornerstone of this PPG. This Core will continue to develop or improve and provide sophisticated orthotopic tumor models - syngeneic tumor grafts (all four Projects) - as well as cranial window (Projects 1), lung window (Project 2), liver tumor preparation (Project 2, 3) and abdominal window (Project 4). These will enable in vivo time-course monitoring of molecular, cellular, anatomical, and functional parameters in the orthotopic organ environment of brain, colon, liver and pancreatic tumors and their metastases. In addition, this Core will significantly expand maintenance and provision of GEM models in this revised PPG in order to meet a surge of GEM demand from all 4 Projects to study the role of the host microenvironment in response to treatment in spontaneous tumors. Through his leadership of the operation of Cox-7 gnotobiotic animal facility. Dr. Huang will continue to ensure that all experimental animals are of uniform quality and free of murine viruses, pathogenic bacteria, and parasites. This will enable the PPG team to carry out all experimental procedures without the use of antibiotics. These studies are extremely difficult and more costly elsewhere. Currently 26 defined-flora genetically engineered mouse lines are available in the Cox-7 facility. Based on the need of all 4 Projects, additional mouse lines will also be engineered or rederived, bred, and produced within the facility. Tumors that are screened and free of mouse pathogens will be serially passaged in vivo and implanted into experimental animals within the colony. In vivo tumors will not be passaged beyond the fifth generation (F5) to avoid changes in tumor characteristics. This assures tight control of the quality of animals and tumors. Core C will continue to provide standard animal procedures such as controlled-release pump implantation, vascular line placement, post-surgical care and tissue collection.